10.31
-0.34 (-3.19%)
| Previous Close | 10.65 |
| Open | 10.61 |
| Volume | 2,853,420 |
| Avg. Volume (3M) | 2,439,559 |
| Market Cap | 1,279,172,096 |
| Price / Earnings (TTM) | 51.55 |
| Price / Earnings (Forward) | 29.50 |
| Price / Sales | 4.96 |
| Price / Book | 2.14 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Profit Margin | 9.85% |
| Operating Margin (TTM) | 0.80% |
| Diluted EPS (TTM) | 0.200 |
| Quarterly Revenue Growth (YOY) | 29.60% |
| Quarterly Earnings Growth (YOY) | 3,119.20% |
| Total Debt/Equity (MRQ) | 42.63% |
| Current Ratio (MRQ) | 10.80 |
| Operating Cash Flow (TTM) | 66.51 M |
| Levered Free Cash Flow (TTM) | 49.10 M |
| Return on Assets (TTM) | 0.06% |
| Return on Equity (TTM) | 4.48% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | Dynavax Technologies Corporatio | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 1.63 |
|
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 0.48% |
| % Held by Institutions | 107.36% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Chicago Capital, Llc | 31 Mar 2025 | 5,344,570 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 33.00 (Citizens Capital Markets, 220.08%) | Buy |
| Median | 31.00 (200.68%) | |
| Low | 10.00 (Goldman Sachs, -3.01%) | Sell |
| Average | 24.67 (139.28%) | |
| Total | 2 Buy, 1 Sell | |
| Avg. Price @ Call | 12.32 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 17 Apr 2025 | 10.00 (-3.01%) | Sell | 10.31 |
| 11 Feb 2025 | 12.00 (16.39%) | Sell | 12.70 | |
| Citizens Capital Markets | 21 Feb 2025 | 33.00 (220.08%) | Buy | 13.33 |
| HC Wainwright & Co. | 21 Feb 2025 | 31.00 (200.68%) | Buy | 13.33 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |